CTA
CSTL icon

Colonial Trust Advisors’s Castle Biosciences CSTL Stock Holding History

Colonial Trust Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6
Closed -$131 – 755
2024
Q2 		$131 Hold
6
– – ﹤0.01% 741
2024
Q1 		$133 Hold
6
– – ﹤0.01% 1001
2023
Q4 		$129 Hold
6
– – ﹤0.01% 890
2023
Q3 		$101 Hold
6
– – ﹤0.01% 903
2023
Q2 		$82 Hold
6
– – ﹤0.01% 903
2023
Q1 		$136 Hold
6
– – ﹤0.01% 883
2022
Q4 		$141 Buy
+6
New +$139 ﹤0.01% 887

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Colonial Trust Advisors's CSTL Position: Q3 2024 in Review

Colonial Trust Advisors sold out of Castle Biosciences (CSTL) in Q3 2024, closing a stake of 6 shares — an estimated $131 sold.

Colonial Trust Advisors first reported a position in CSTL in Q4 2022 and held it in 7 quarters. The position peaked at $141 in Q4 2022. 185 funds tracked by Wall St. Rank hold CSTL as of Q3 2024.

  • Colonial Trust Advisors reported no remaining Castle Biosciences position as of Q3 2024 after selling out during the quarter.
  • Colonial Trust Advisors sold 6 Castle Biosciences shares in Q3 2024, an estimated $131.
  • Colonial Trust Advisors first reported a position in Castle Biosciences in Q4 2022 and held it in 7 quarters.
  • Colonial Trust Advisors's Castle Biosciences position peaked at $141 in Q4 2022.
  • 185 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2024.

Based on Colonial Trust Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.